Who We Are
We’re a young and talented group of scientists and innovators pursuing groundbreaking ideas designed to contribute towards a better tomorrow. At Inspira, we have a relentless focus on what is possible, we thrive on experimentation and collaboration, and we embrace ideas that break with convention. Contact us today for more information or a press pack.
Our research centres on identifying and evaluating novel molecules that have the potential to become high-impact therapeutic products.
In 2021, Inspira commenced preclinical research at the University of Oxford to determine the virucidal activity of our IPX formulations using the live SARS-CoV-2 virus.
Our IPX formulations have displayed promising virucidal activity against SARS-CoV-2 and we believe they have the ability to rapidly degrade or destroy the SARS-CoV-2 viral spike proteins. Our work will now focus on testing and developing our technology to prepare for human trials.
In 2022 we were selected for a research grant from Innovate UK, the UK's main research funding body. This co-financed project is focussed on proof-of-concept research to test novel molecules against bacterial biofilms. Our research focusses on the inhibition and disruption of biofilm, which can be difficult to treat as some biofilms are antibiotic resistant and higher drug doses are often needed to reach sites of infection (particularly with lower respiratory tract infections). Results so far have been very encouraging and we are excited to be rapidly advancing this research.